Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Putting Malaria Bugs Back On The Defensive


Developments to Watch

PUTTING MALARIA BUGS BACK ON THE DEFENSIVE

Malaria ravages the developing world: Across Africa, Asia, and Latin America, some 500 million people suffer from it--and 2 million of them, mainly children, die each year. Things have gotten worse in the past decade, as the malaria parasite has developed resistance to chloroquine, the standard drug used to treat the disease.

Now, Dr. Daniel E. Goldberg of Washington University School of Medicine in St. Louis, Mo., is developing new drugs to tackle the wily bug. It normally invades red blood cells and uses powerful enzymes to devour oxygen-carrying hemoglobin, from which it steals components to fuel attacks on other cells. Goldberg hopes to starve the parasite by blocking the enzymes' ability to chew up hemoglobin. He has identified several promising drugs that mimic a tasty site on the hemoglobin. The enzymes bind to these drugs instead of the hemoglobin and are rendered harmless. Monsanto Co. is helping to fund the research, and animal tests could begin in a year.EDITED BY ROBERT BUDERI


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus